Health and Fitness Health and Fitness
Wed, August 4, 2010
[ 03:30 AM ] - Market Wire
Concerned Osteotech Stockholders Announce Nominat .. bers to the Board of Directors of Osteotech, Inc.
[ 03:10 AM ] - Market Wire
UnitedHealth Group Board Authorizes Payment of Quarterly Dividend to Shareholders
[ 01:45 AM ] - Market Wire
Theragenics to Report Second Quarter 2010 Financial Results Tuesday, August 10
[ 01:45 AM ] - Market Wire
Tenet Announces Pricing of Its Private Offering of Senior Notes due 2020
[ 01:45 AM ] - Market Wire
ZymoGenetics to Webcast Presentation at the Canaccord Annual Growth Conference
Tue, August 3, 2010
[ 04:40 PM ] - Market Wire
Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Almost Family, Inc.
[ 02:18 PM ] - Market Wire
Humana Military Healthcare Services Named in the .. for Military Times 2010 aBest Employers for Vetsa
[ 11:05 AM ] - Market Wire
Neurocrine Biosciences, Big 5 Sporting Goods, Aetna, CVS Caremark and Express Scripts
[ 11:05 AM ] - Market Wire
Humana, Unitedhealth, Allergan, Medicis Pharma and Johnson & Johnson
[ 10:41 AM ] - Market Wire
Enzon Reports Second Quarter 2010 Results
[ 10:35 AM ] - Market Wire
Five Prime Therapeutics, Inc. Announces Strategic .. e to Discover Innovative Biologics for Skeletal M
[ 10:35 AM ] - Market Wire
AMAG Pharmaceuticals, Inc. to Present at Canaccord Genuity 30th Annual Global Growth Conference
[ 10:35 AM ] - Market Wire
Array BioPharma to Report Financial Results for t .. er and Full Year of Fiscal 2010 on August 9, 2010
[ 10:35 AM ] - Market Wire
DexCom Inc. Reports Second Quarter 2010 Financial Results
[ 10:35 AM ] - Market Wire
ArQule en Daiichi Sankyo gaan door met fase-3 kli .. lan voor ARQ 197 bij niet-kleincellige longkanker
[ 10:35 AM ] - Market Wire
ArQule e Daiichi Sankyo avanzano alla fase 3 del .. ica della?ARQ 197 in pazienti affetti da carcinom
[ 10:35 AM ] - Market Wire
Teva Receives European Commission Approval for ratiopharm Acquisition
[ 08:05 AM ] - Market Wire
Life Technologies Provides Notice of Contingent I .. est Payment to 2% Convertible Senior Note Holders
[ 08:05 AM ] - Market Wire
SRI/Surgical Express, Inc. Second Quarter 2010 Conference Call
[ 08:05 AM ] - Market Wire
NeuroMetrix to Present at Canaccord Genuity 30th Annual Growth Conference
[ 08:05 AM ] - Market Wire
MiddleBrook Pharmaceuticals Completes Sale of Assets
[ 08:05 AM ] - Market Wire
NeuroMetrix, Inc. Announces Date for 2010 Second Quarter Financial Results Conference Call
[ 08:05 AM ] - Market Wire
Spectranetics to Present at the Canaccord Genuity .. 30th Annual Global Growth Conference on August 10
[ 08:05 AM ] - Market Wire
Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Genentech
[ 08:05 AM ] - Market Wire
Curis Reports Second Quarter 2010 Financial Results
[ 08:05 AM ] - Market Wire
Curis Announces Dosing of First Patient in CUDC-101 Phase Ib Expansion Trial
[ 08:05 AM ] - Market Wire
MEDNAX Earns $1.04 Per Share in 2010 Second Quarter
[ 07:55 AM ] - Market Wire
IMRIS announces appointments to leadership team
[ 07:45 AM ] - Market Wire
ArQule und Daiichi Sankyo schreiten mit Plan fr k .. RQ 197 zur Behandlung von nicht-kleinzelligem Lun
[ 07:30 AM ] - Market Wire
Aeterna Zentaris to Present at Upcoming Canaccord .. y 30th Annual Growth Conference 2010 on August 12

Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 12


Published on 2010-08-03 07:40:26 - Market Wire
  Print publication without navigation


QUÉBEC CITY, Aug. 3 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, MD, will present a corporate overview at the upcoming Canaccord Genuity 30th Annual Growth Conference on Thursday, August 12, 2010, at 3:00 p.m. ET, in the Montreal Room of the InterContinental Boston, in Boston.

A live webcast of the presentation will be available on Aeterna Zentaris' website at [ www.aezsinc.com ] in the Investors section. A replay will also be available for a period of 30 days on the Company's website.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are available at [ www.aezsinc.com ].

Contributing Sources